{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"6.190","floor":"5.160"},"ipodate":{"start":"2015-06-25 00:00:00","end":"2015-06-30 00:00:00"},"minimumcapital":"3126.00","subscribed":"38.80","marketcap":"13.46億","H_marketcap":"--","pe":"39.03","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/01498/LTN20150625050_C.pdf","ipopricing":"5.980","resultdate":"2015-07-07 00:00:00","enddate":"2015-06-30 00:00:00","listeddate":"2015-07-08 00:00:00","issuenumber":"7113.00萬","issuenumberhK":"2133.90萬","issuenumberother":"4979.10萬","grayprice":"5.50","sponsors":"交銀國際(亞洲)有限公司","raisemoney":"28890.00萬","use":"1、約30.0%或86.7百萬港元將用作擴建生產設施及為現有生產線進行升級；\n2、約25.0%或72.2百萬港元將用作在香港及中國成立新的農本方?中醫診所；\n3、約20.0%或57.8百萬港元用作擴展我們的分銷網絡至中國的新目標城市，主要透過與國藥控股合作付諸實行，包括：(i)為新客戶購買農本方?智能中醫診所管理及配藥系統設備（每個藥房系統的平均成本為150,000港元）；(ii)就農本方?智能中醫診所管理及配藥系統的運營及維護培訓新的分銷商及醫院員工；(iii)提供售后及維護服務；(iv)在中國的獲批準醫院及醫療機構成立及裝修我們從事直接銷售的中藥房；\n4、約15.0%或43.3百萬港元用作為下列兩種新中成藥產品的開發及推廣（包括：(i)完成中國規定的臨床試驗；(ii)香港及中國的新產品注冊；及(iii)有關測試、抽樣及項目管理）提供資金；\n5、約10.0%或28.9百萬港元將用作我們的營運資金及其他一般公司用途。","shares":500,"leadagent":"交銀國際證券有限公司,星展亞洲融資有限公司","bookrunners":"交銀國際證券有限公司","coordinator":"交銀國際證券有限公司","firstDayOpen":"4.77","IsEiio":0,"Interestdays":7,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"交銀國際證券有限公司","code":"E01498","name":"培力控股","fullname":"培力控股有限公司"},"institutioninfo":{"principaloffice":"香港中環康樂廣場1號怡和大廈4002室","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628 ","chairman":"陳宇齡","secretary":"劉家權","telephone":"(852) 2840 1840","substantialshareholders":"陳宇齡及關連人士(52.47%)","principalactivities":"公司是一家以香港為基地的領先中醫藥公司，以旗下「農本方」品牌從事濃縮中藥配方顆粒產品的研發、生產、市場推廣及銷售。","website":"http://www.purapharm.com"},"managerinfo":[],"investorinfo":[],"TotalShareholdingPercentage":0},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":524}